In line with these findings, caspase-3 activation - as indicated by p19 and p17 cleavage products - and cleavage of the caspase-3 substrate Poly-(ADP-ribose)-Polymerase (PARP) was only observed in the lysates of ErPC3-treated prostate cancer cells but not in the lysates of irradiated prostate cancer cells (Figure 3A and Figure 3B). The gene discussed is CASP3; the disease is prostate carcinoma.